Collegium Pharmaceutical, Inc. (COLL)
| Market Cap | 620.51M |
| Revenue (ttm) | 325.78M |
| Net Income (ttm) | 103.51M |
| Shares Out | 34.57M |
| EPS (ttm) | 2.69 |
| PE Ratio | 6.67 |
| Forward PE | 4.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 367,004 |
| Open | 19.30 |
| Previous Close | 18.53 |
| Day's Range | 17.57 - 18.49 |
| 52-Week Range | 17.67 - 26.91 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 25.14 (+40.1%) |
| Earnings Date | Nov 4, 2021 |
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to C...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 25.14, which is an increase of 40.06% from the latest price.
News
Collegium Announces $25 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...
UPDATE: Collegium to Participate in Upcoming Conferences
STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...
Collegium Participate in Upcoming Conferences
STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...
Collegium Pharmaceutical (COLL) Misses Q3 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -76.09% and -6.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announ...
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
COLL vs. ZTS: Which Stock Is the Better Value Option?
Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today...
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today...
Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance
Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 adjusted EPS of $0.27, below the consensus of $0.36. The reported EPS of $1.79 was up from $0.23 a year ago and included a one-time non-cash adjus...
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million
– Xtampza ® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 –
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 202...
Collegium Announces Publication of Real-World Data in Journal of Pain Research
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...
Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
Collegium to Participate in Upcoming Investor Conference
STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today a...
Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Collegium Reports Record Quarterly Revenue of $87.7 Million
– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 –
Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6,...
Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition –
Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, Februar...
Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday
It's not every day that a company graduates to a slot in a high-profile stock index.